BioTuesdays

Category - Markets

Tocagen Logo
Markets

HCW starts Tocagen at buy; PT $14.50

H.C. Wainwright initiated coverage of Tocagen (NASDAQ:TOCA) with a “buy” rating and price target of $14.50. The stock closed at $9.64 on June 8. Analyst Swayampakula Ramakanth writes that the company’s lead product...

June 11, 2018
Axsome Therapeutics
Markets

HCW starts Axsome Therapeutics at buy; PT $10

H.C. Wainwright initiated coverage of Axsome Therapeutics (NASDAQ:AXSM) with a “buy” rating and price target of $10. The stock closed at $3.60 on June 6. Axsome, which is focused on central nervous system (CNS)...

June 7, 2018
Marinus Pharma
Markets

Ladenburg starts Marinus Pharma at buy; PT $20

Ladenburg Thalmann launched coverage of Marinus Pharmaceuticals (NASDAQ:MRNS) with a “buy” rating and $20 price target. The stock closed at $6.74 on June 5. Marinus is developing ganaxolone (GNX), a synthetic analog of...

June 6, 2018
Voyager Therapeutics
Markets

​HCW starts Voyager Therapeutics at buy; PT $30

H.C. Wainwright initiated coverage of Voyager Therapeutics (NASDAQ:VYGR) with a “buy” rating and $30 price target, saying the company is assembling a neuro-focused gene therapy franchise. The stock closed at $20.41 on...

June 5, 2018
Viking Therapeutics Logo
Markets

Roth ups Viking Therapeutics PT to $13

Roth Capital Partners hiked its price target for Viking Therapeutics (NASDAQ:VKTX) to $13 from $7.50, saying Viking is the beneficiary of competitive data that validates its VK2809 drug candidate. The stock closed at $9...

June 1, 2018
T2 Biosystems Logo
Markets

Leerink ups T2 Biosystems to OP; PT to $12

Leerink upgraded T2 Biosystems (NASDAQ:TTOO) to “outperform” from “market perform” and raised its price target to $12 from $5. The stock closed at $7.74 on May 31. Analyst Puneet Souda writes that this week’s...

June 1, 2018
Arcturus Logo
Markets

Ladenburg ups Arcturus Therapeutics to buy; PT $22

Ladenburg Thalmann upgraded Arcturus Therapeutics (NASDAQ:ARCT) to “buy” from “neutral” with a $22 price target after the company resolved a management dispute, “removing an organizational overhang since early February...

June 1, 2018
Exact Sciences Logo
Markets

BTIG ups Exact Sciences PT to $70 from $60

BTIG raised its price target for Exact Sciences (NASDAQ:EXAS) to $70 from $60 after the American Cancer Society expanded colorectal cancer screening guidelines. Shares of Exact were quoted at $57.99, up 10%, in...

May 30, 2018
ASLAN Pharmaceuticals
Markets

BTIG starts ASLAN Pharma at buy; PT $16

BTIG launched coverage of ASLAN Pharmaceuticals (NASDAQ:ASLN) with a “buy” rating and $16 price target. The stock closed at $6.85 on May 29. Singapore-based ASLAN is engaged in the development and commercialization of...

May 30, 2018